Why insider trading matters?
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
- Peter Lynch
Why insider trading matters?
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2020-06-30 | CRANSTON MARY B | Director | Sell | 22,000 | $96.63 | $2,125,966 | No |
| 2020-07-02 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $93.98 | $469,909 | No |
| 2020-06-30 | CRANSTON MARY B | Director | Sell | 22,000 | $96.63 | $2,125,966 | Yes |
| 2020-06-02 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $102.84 | $514,208 | No |
| 2020-05-18 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 10,000 | $125.00 | $1,250,000 | No |
| 2020-05-11 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 25,000 | $101.86 | $2,546,477 | No |
| 2020-05-04 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $58.48 | $292,387 | No |
| 2020-04-20 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 1,000 | $55.00 | $55,000 | No |
| 2020-04-08 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 1,500 | $50.00 | $75,000 | No |
| 2020-04-06 | Harris Taylor C. | Chief Financial Officer | Sell | 1,305 | $46.99 | $61,322 | Yes |
| 2020-04-02 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 2,500 | $44.77 | $111,917 | No |
| 2020-03-02 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $64.45 | $322,246 | No |
| 2018-05-04 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 3,000 | $47.57 | $142,700 | Yes |
| 2020-02-03 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $69.36 | $346,821 | No |
| 2020-02-01 | Fairey William | See Remarks | Sell | 2,899 | $68.04 | $197,248 | Yes |
| 2020-01-14 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $75.39 | $376,964 | No |
| 2020-01-06 | Harris Taylor C. | Chief Financial Officer | Sell | 1,683 | $68.45 | $115,203 | No |
| 2020-01-06 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 12,687 | $68.45 | $868,439 | No |
| 2020-01-06 | McDowell Robert Scott | Chief Scientific Officer | Sell | 2,650 | $68.45 | $181,395 | No |
| 2020-01-06 | LADD CYNTHIA J | General Counsel | Sell | 1,849 | $68.45 | $126,566 | No |
| 2020-01-06 | Bauer Jake | Chief Business Officer | Sell | 2,466 | $68.45 | $168,800 | Yes |
| 2020-01-03 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $71.80 | $359,008 | Yes |
| 2019-12-20 | Bauer Jake | Chief Business Officer | Sell | 18,916 | $70.07 | $1,325,421 | Yes |
| 2019-12-02 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $65.02 | $325,098 | No |
| 2019-11-29 | Bauer Jake | Chief Business Officer | Sell | 21,232 | $65.31 | $1,386,687 | No |
| 2019-11-04 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $59.07 | $295,364 | No |
| 2019-10-03 | GIANAKAKOS ANASTASIOS | President and CEO | Sell | 5,000 | $52.82 | $264,111 | No |
| 2019-09-23 | Lee June | EVP, Chief Development Officer | Sell | 13,051 | $59.51 | $776,724 | Yes |
| 2019-09-20 | Bauer Jake | Chief Business Officer | Sell | 19,700 | $60.09 | $1,183,777 | Yes |
| 2019-09-19 | Lee June | EVP, Chief Development Officer | Sell | 5,435 | $57.08 | $310,254 | Yes |
Insider Smart
Insider Smart